Table 1. FDA approved PARP inhibitors.

Drug	Date of FDA Approval	Population	Indication	Dosing	References	Specificity	Ki	Relative trapping capacity (28,29)
Olaparib	2017	gBRCAm advanced ovarian cancer	Received three or more prior lines of chemotherapy	300 mg BID	(30)	PARP1, PARP2	5 nM, 1 nM	+++
	2018	Recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer	Tumors must have CR/PR to platinum-based chemotherapy	300 mg BID	(31)
	2018	gBRCAm HER2-negative metastatic breast cancer	Previous treatment with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting	300 mg BID	(32)
	2019	gBRCAm metastatic pancreatic adenocarcinoma	No disease progression after 16 weeks of a first-line platinum-based chemotherapy regimen	300 mg BID	(30)
Rucaparib	2018	Recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer	Tumors must have CR/PR to platinum-based chemotherapy	600 mg BID	(33)	PARP1	4 nM	+++
Niraparib	2017	Recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer	Tumors must have CR/PR to platinum-based chemotherapy	300 mg QD	(34)	PARP1, PARP2	3.2 nM, 4 nM	++++
	2019	Advanced ovarian, fallopian tube, primary peritoneal cancer with HRD-positive status	Previous treatment with three or more chemotherapy regimens	300 mg QD	(35)
Talazoparib	2018	gBRCAm HER2-negative breast cancer, locally advanced or metastatic	Patient selection for therapy is based on FDA-approved companion diagnostic for talazoparib	1 mg QD	(36)	PARP1, PARP2	1.2 nM, 0.9 nM	+++++

Data as of February 2020. PARP, poly (ADP-ribose) polymerase; gBRCAm, germline BRCA-mutated; CR, complete response; PR, partial response; BID, twice daily; QD, once daily; Ki, catalytic inhibitory constant; HRD, homologous recombination deficiency; HER2, human epidermal growth factor receptor 2.